veyrier
du
lac
franc
cohost
two
gvn
center
excel
foundat
univers
veterinari
medicin
hannov
tiho
theme
intern
gvn
meet
erad
control
emerg
virus
report
highlight
recent
accomplish
gvn
research
sever
import
area
medic
virolog
includ
strategi
erad
smallpox
measl
polio
sar
vectorborn
zoonot
infect
emerg
intervent
strategi
retrovirus
arbovirus
prepared
outbreak
filoand
hemophil
virus
pathogenesi
impact
prevent
respiratori
virus
well
virus
affect
central
peripher
nervou
system
also
threat
crisi
set
like
refuge
camp
present
global
viru
network
wwwgvnorg
notfor
profit
organ
cofound
robert
c
gallo
md
institut
human
virolog
ihv
univers
maryland
school
medicin
baltimor
md
usa
william
hall
md
phd
univers
colleg
dublin
ireland
late
reinhard
kurt
md
phd
robert
koch
institut
berlin
germani
concept
gvn
origin
dr
gallo
realiz
lack
global
direct
research
caus
aid
network
compris
center
excel
affili
institut
throughout
world
gvn
center
affili
led
expert
independ
global
virologist
pillar
organ
mission
gvn
strengthen
medic
research
respond
current
viral
caus
human
diseas
prepar
new
viral
pandem
threat
gvn
meet
mission
three
way
research
advocaci
train
gvn
vision
world
better
prepar
control
prevent
viral
epidem
threat
collabor
global
network
expert
virologist
part
gvn
research
program
includ
intern
scientif
meet
present
discuss
current
find
medic
veterinari
virolog
applic
exist
emerg
virus
global
import
explor
new
approach
prevent
treatment
cure
infecti
diseas
engag
inspir
earli
career
scientist
advanc
virolog
research
promot
collabor
among
world
expert
virologist
past
candid
publish
import
scientif
inform
virolog
area
interest
gvn
includ
limit
basic
scienc
clinic
aspect
pathogenesi
epidemiolog
diagnost
antivir
vaccin
develop
candid
made
consequenti
meaning
contribut
gvn
further
mission
gvn
includ
limit
develop
network
center
excel
particip
train
program
contribut
meet
gvn
activ
contribut
advocaci
public
commun
activ
awarde
erica
ollmann
saphir
phd
michael
ba
oldston
md
scripp
research
institut
la
jolla
ca
usa
mariano
esteban
nation
center
biotechnolog
madrid
spain
review
histori
smallpox
erad
vaccin
current
avail
vaccin
diagnost
antivir
smallpox
relat
orthopoxvirus
smallpox
highli
virul
human
viru
mortal
children
adult
result
estim
million
death
mount
worldwid
vaccin
campaign
diseas
declar
erad
howev
viru
maintain
russia
unit
state
research
purpos
world
health
assembl
determin
whether
stock
destroy
viru
could
reconstruct
avail
sequenc
inform
need
vaccin
diagnost
antivir
avail
case
outbreak
new
vaccin
includ
mva
gener
pox
vector
new
monoclon
antibodi
improv
diagnosi
poxviru
egress
inhibitor
effect
monkeypox
deliv
oral
intraven
plan
develop
second
antivir
differ
mechan
action
dian
e
griffin
john
hopkin
bloomberg
school
public
health
baltimor
md
usa
review
statu
measl
prospect
erad
although
substanti
progress
measl
control
erad
technic
feasibl
case
increas
mani
part
world
due
failur
vaccin
measl
viru
effici
transmit
high
level
popul
immun
requir
elimin
endem
spread
achiev
level
popul
immun
requir
dose
live
attenu
vaccin
first
dose
deliv
month
age
second
school
entri
supplement
vaccin
activ
difficult
sustain
vaccin
safe
provid
protect
infect
protect
less
robust
longlast
wildtyp
infect
provid
lifelong
immun
differ
immun
respons
may
relat
fact
infect
wildtyp
measl
viru
result
longterm
persist
viral
rna
lymphoid
tissu
vaccin
viru
infect
barrier
achiev
level
immun
requir
erad
includ
lack
polit
logist
difficulti
vaccin
deliveri
unfound
fear
vaccin
hazard
michel
zaffran
world
health
organ
geneva
switzerland
review
current
statu
effort
erad
polio
global
polio
erad
initi
publicpriv
partnership
launch
base
vaccin
trival
live
oral
polioviru
opv
vaccin
consider
success
decreas
case
paralysi
appar
elimin
wild
polioviru
wpv
type
howev
seen
increas
case
wpv
type
case
confirm
date
pakistan
afghanistan
associ
mani
chain
transmiss
along
border
two
countri
conflict
zone
lack
trust
complic
surveil
well
vaccin
deliveri
addit
ongo
problem
circul
vaccinederiv
pv
usual
opv
type
mani
region
counter
problem
type
remov
opv
three
countri
initi
vaccin
inactiv
trival
vaccin
ipv
rather
opv
leo
poon
univers
hong
kong
school
public
health
hong
kong
china
review
histori
outbreak
sever
acut
respiratori
syndrom
sar
coronaviru
caus
almost
death
biggest
impact
china
hong
kong
singapor
canada
control
achiev
case
isol
prevent
nosocomi
spread
contact
trace
quarantin
remain
risk
return
viral
reservoir
chines
horsesho
bat
may
transmit
infect
speci
joaquim
segal
cresacent
de
recerca
en
sanitat
anim
barcelona
spain
present
overview
viru
transmiss
anim
human
note
emerg
reemerg
diseas
caus
rna
virus
vectorborn
zoonot
prevent
requir
one
health
approach
control
origin
focu
viru
reservoir
segment
infect
chain
amen
intervent
howev
reservoir
identif
alway
easi
new
method
use
larg
genom
ecolog
dataset
machin
learn
evolutionari
criteria
predict
anim
reservoir
rna
virus
approach
decreas
time
viru
discoveri
control
georg
thiri
coalit
epidem
prepared
innov
cepi
toulous
franc
explain
plan
cepi
facilit
fund
develop
vaccin
prioriti
pathogen
cepi
found
partnership
public
privat
philanthrop
civil
organ
first
group
target
pathogen
mer
coronaviru
candid
vaccin
lassa
viru
candid
nipah
viru
candid
chosen
base
public
health
impact
risk
outbreak
vaccin
feasibl
plan
bring
vaccin
candid
late
preclin
develop
manufactur
dose
second
call
plan
propos
develop
platform
decreas
vaccin
develop
new
pathogen
week
sharon
lewin
peter
doherti
institut
infect
immun
univers
melbourn
royal
melbourn
hospit
melbourn
australia
present
recent
publish
unpublish
work
natur
variat
hiv
transcript
hivinfect
individu
antiretrovir
therapi
art
specif
effect
time
circadian
protein
vari
cours
day
stress
current
high
interest
understand
hiv
persist
individu
art
order
develop
novel
strategi
elimin
longliv
latent
viru
overal
goal
individu
safe
stop
art
without
viru
rebound
lewin
one
first
demonstr
mani
year
ago
ongo
transcript
viru
individu
fulli
suppress
art
detect
cellassoci
unsplic
multipli
splice
rna
lewin
et
al
group
demonstr
hiv
transcript
art
vari
time
circadian
protein
circadianlocomotoroutputcycleskaput
clock
bind
ebox
hiv
long
termin
repeat
ltr
promot
enhanc
transcript
chang
et
al
protein
could
potenti
exploit
latenc
revers
also
present
recent
data
intervent
studi
stress
stimulu
demonstr
stress
also
increas
basal
level
hiv
transcript
individu
art
joshua
anzing
univers
west
indi
kingston
jamaica
review
epidemiolog
manag
hiv
infect
caribbean
defin
world
health
organis
present
publish
data
unaid
demonstr
number
peopl
live
hiv
region
adult
preval
total
aidsrel
death
risk
factor
predominantli
heterosexu
transmiss
except
jamaica
men
sex
men
common
risk
factor
sex
work
infect
inject
drug
use
rare
except
puerto
rico
bermuda
preval
sex
worker
highest
haiti
relat
reach
unaid
target
peopl
awar
diagnosi
treatment
suppress
viral
load
caribbean
current
progress
toward
target
vari
differ
countri
jamaica
recent
advanc
includ
polici
testandtreat
introduc
januari
pilot
program
preexposur
prophylaxi
start
seven
countri
caribbean
achiev
elimin
mothertochild
transmiss
hiv
antoin
gessain
institut
pasteur
pari
present
updat
gessain
highlight
signific
preval
indigen
commun
central
australia
shortli
follow
signific
public
media
interest
indigen
australian
follow
gvn
meet
held
melbourn
septemb
catton
et
al
australian
govern
announc
establish
task
forc
respond
fund
million
australian
dollar
bold
invest
gessain
also
present
preliminari
data
new
larg
prospect
studi
infect
gabon
preliminari
data
first
particip
enrol
show
preval
infect
increas
age
higher
women
men
higher
pygmi
ethnic
group
likelihood
infect
also
margin
higher
individu
histori
bite
nonhuman
primat
djuici
et
al
predomin
subtyp
central
africa
subtyp
emphas
asid
japan
true
preval
world
urgent
need
evalu
robert
c
gallo
institut
human
virolog
univers
maryland
baltimor
md
highlight
mani
virus
mechanist
associ
human
cancer
howev
associ
bacteria
cancer
helicobact
pylori
poorli
understood
multipl
strain
mycoplasma
bacterium
capabl
intracellular
infect
associ
develop
cancer
mice
human
show
type
mycoplasma
fermenten
infect
mous
human
lymphocyt
produc
lymphoma
immunodefici
mice
evid
mycoplasma
tumor
develop
except
small
less
kb
dna
fragment
small
number
tumor
cell
fragment
includ
compon
dnak
protein
produc
multipl
bacteria
protein
markedli
reduc
proapoptot
activ
interact
protein
dna
repair
complex
addit
protein
impair
activ
anticanc
drug
depend
enhanc
zella
et
al
preliminari
data
show
fragment
detect
human
lymphoma
sequenc
differ
found
mice
conclud
find
consist
hit
run
strategi
mycoplasma
caus
malign
johan
neyt
univers
leuven
leuven
belgium
discuss
antivir
drug
develop
program
institut
despit
success
hiv
hepat
b
c
herpesvirus
licens
antivir
vast
major
viral
pathogen
use
cellbas
antivir
screen
high
contain
robot
labinabox
antivir
pursu
wide
varieti
virus
exampl
present
potent
compound
target
four
dengu
viru
serotyp
nanomolar
concentr
anoth
novel
class
chikungunya
viru
inhibitor
also
activ
venezuelan
equin
enceph
viru
micromolar
concentr
compound
target
rna
cap
function
alphaviru
protein
influenza
viru
inhibitor
favipiravir
also
shown
activ
flavivirus
arenavirus
bunyavirus
filovirus
addit
effort
evalu
capsidbind
well
novel
compound
bind
site
target
rhinovirusesenterovirus
order
prevent
excret
wildtyp
vaccin
polioviru
strain
immunocompromis
individu
strategi
evalu
conjunct
inactiv
polioviru
vaccin
novel
enteroviru
rhinoviru
inhibitor
show
unusu
high
barrier
develop
resist
target
protein
highli
effect
mous
model
final
cmethylcytidin
protect
mice
fatal
mous
noroviru
infect
also
prevent
transmiss
promis
control
human
norovirus
major
etiolog
agent
human
diarrheal
diseas
johan
collabor
mani
intern
virolog
research
group
hope
use
uniqu
labinabox
facil
partner
addit
gvn
center
mauricio
nogueira
faculti
medicin
sao
jose
rio
preto
present
updat
yellow
fever
yf
outbreak
africa
brazil
began
point
understand
yf
viru
transmiss
ecolog
possibl
control
strategi
alreadi
establish
centuri
ago
littl
progress
new
develop
recent
decad
due
enzoot
transmiss
cycl
nonhuman
primat
nhp
popul
contin
erad
viru
imposs
risk
spillov
emerg
epidem
alway
remain
constant
threat
ever
sinc
develop
yfv
vaccin
effort
mitig
threat
emerg
focus
prevent
vaccin
human
popul
risk
brazil
sever
genera
nhp
serv
enzoot
host
haemagogu
sabeth
aed
spp
mosquito
serv
vector
major
human
infect
asymptomat
develop
lifethreaten
hemorrhag
diseas
epidem
angola
democrat
republ
congo
involv
ca
confirm
case
fatal
mani
suspect
case
approxim
million
peopl
vaccin
deplet
intern
vaccin
stockpil
includ
brazil
largest
manufactur
countri
outbreak
ensu
brazil
confirm
case
death
along
thousand
fatal
nhp
infect
deficit
yf
vaccin
coverag
known
endem
region
combin
spread
region
without
outbreak
mani
decad
consequ
minim
vaccin
respons
largest
epidem
mani
year
etiolog
yfv
strain
appear
origin
sao
paulo
state
enzoot
amplif
occur
forest
urban
pocket
marmoset
particularli
abund
fraction
dose
yf
vaccin
appear
efficaci
probabl
manufactur
includ
larger
viru
titer
requir
howev
vaccin
occasion
produc
seriou
sometim
fatal
advers
reaction
prompt
develop
inactiv
version
vaccin
platform
develop
sporad
natur
outbreak
make
efficaci
trial
challeng
mauricio
also
discuss
evid
nhp
infect
zika
viru
brazil
potenti
zika
like
yfv
establish
enzoot
sylvat
cycl
amazon
region
south
america
marc
lecuit
institut
pasteur
pari
franc
present
overview
intern
collabor
research
program
address
divers
etiolog
pediatr
infecti
enceph
southeast
asia
project
conduct
referr
hospit
juli
decemb
hanoi
vietnam
phnom
penh
cambodia
vientian
lao
pdr
yangon
myanmar
children
clinic
acut
enceph
syndrom
prospect
enrol
comprehens
laboratori
diagnost
perform
use
molecular
serolog
test
target
encephalitiscaus
pathogen
enrol
children
met
ae
case
definit
median
age
year
male
mri
abnorm
caus
pathogen
identifi
preliminari
result
show
japanes
enceph
viru
jev
herp
simplex
viru
influenza
viru
dengu
viru
enteroviru
streptococcu
pneumonia
orientia
tsutsugamushi
mycobacterium
tuberculosi
common
pathogen
detect
outcom
fatal
neurolog
sequela
present
patient
low
glasgow
score
short
breath
admiss
significantli
associ
death
identifi
etiolog
prevent
curabl
underscor
clinic
relev
strengthen
local
capac
conduct
pathogenspecif
diagnost
present
highlight
fact
despit
widespread
use
je
vaccin
across
se
asian
region
jev
remain
predomin
pathogen
identifi
differenti
diagnosi
detect
approxim
case
across
site
analysi
requir
assess
je
case
involv
vaccin
failur
howev
mention
routin
deliveri
je
vaccin
within
epi
program
remain
weak
particularli
cambodia
interest
preliminari
data
present
regard
codetect
respiratori
syncyti
viru
rsv
nasopharyng
sampl
ae
case
suggest
possibl
encephalopathi
may
associ
rsv
infect
despit
extens
laboratori
test
use
pathogenspecif
molecular
serolog
assay
etiolog
remain
undetermin
mani
patient
analysi
residu
specimen
next
gener
sequenc
plan
masayuki
saijo
depart
virolog
nation
institut
infecti
diseas
tokyo
japan
provid
updat
je
epidemiolog
japan
region
note
routin
immun
program
japan
still
deploy
inactiv
je
vaccin
biken
vero
cellculturederiv
requir
dose
wherea
live
attenu
vaccin
manufactur
china
singl
dose
becom
wide
use
je
vaccin
endem
countri
averag
number
patient
report
annual
last
sever
year
interestingli
studi
detect
antibodi
jev
indic
natur
infect
demonstr
popul
central
southern
japan
may
infect
annual
highlight
import
continu
vaccin
although
jev
speci
genet
divers
compris
genotyp
recogn
strain
within
speci
serolog
crossreact
thu
consid
singl
serotyp
jev
genotyp
iii
believ
predomin
circul
genotyp
throughout
asia
subsequ
shift
frequent
detect
genotyp
earli
masayuki
present
data
show
genotyp
v
detect
first
time
year
china
south
korea
experi
conduct
use
recombin
virus
evalu
mous
model
suggest
genotyp
v
may
increas
virul
refer
genotyp
iii
strain
addit
protect
efficaci
current
vaccin
genotyp
v
question
base
observ
rel
neutral
titer
sera
vaccin
mice
challeng
jev
strain
genotyp
iii
v
xavier
de
lamballeri
aixmarseil
univers
ird
inserm
marseil
franc
provid
seminar
compel
need
improv
clinic
diagnost
arbovir
diseas
invest
need
interepidem
period
essenti
compon
prepared
current
recur
threat
emphas
largest
burden
diseas
emerg
pathogen
associ
wellknown
pathogen
effect
prevent
control
measur
yet
deploy
talk
address
classic
scenario
emerg
pattern
eg
exampl
anthropomorph
transit
sylvat
urban
cycl
eg
yfv
nonanthropomorph
transit
wherebi
widespread
dissemin
occur
even
absenc
humantohuman
transmiss
eg
west
nile
viru
nonanthropomorph
transit
virus
may
broaden
host
rang
ecolog
nich
chang
land
use
exposur
pattern
eg
tick
born
enceph
final
gener
approach
prepared
effort
propos
align
model
glopidr
http
wwwglopidrorg
work
group
chikungunya
diseas
ann
wildersmith
consult
arbovir
vaccin
whoivb
report
complex
issu
surround
dengu
vaccin
develop
current
usag
provid
overview
basic
concept
regard
heterolog
homolog
immun
respons
serial
infect
differ
serotyp
comprehens
updat
current
understand
perform
characterist
licens
dengu
vaccin
cydtdv
sanofipasteur
dengu
singl
import
arbovir
infect
term
diseas
burden
billion
peopl
risk
infect
estim
million
infect
annual
tropic
subtrop
countri
absenc
truli
effect
sustain
vector
control
measur
dengu
vaccin
consid
key
compon
prevent
program
deploy
dengvaxia
complic
signific
controversi
vaccin
respons
driven
individu
serostatu
vaccin
individu
seroneg
time
inocul
elicit
immun
akin
follow
primari
infect
thu
gener
risk
antibodydepend
enhanc
higher
risk
sever
diseas
upon
subsequ
dengu
infect
contrast
vaccin
individu
seroposit
shown
least
efficaci
protect
subsequ
symptomat
infect
sridhar
et
al
n
engl
j
med
jul
initi
recommend
april
vaccin
deploy
area
seropreval
howev
definit
evid
retrospect
analysi
clinic
trial
data
reveal
excess
sever
dengu
seroneg
vaccin
recipi
sage
strateg
advisori
group
expert
work
group
therefor
oblig
reconsid
guidelin
best
use
vaccin
http
wwwwho
intimmunizationsagepreviousenindexhtml
evalu
circumst
may
net
public
health
benefit
versu
individu
risk
key
consider
whether
recommend
countri
conduct
popul
seropreval
studi
measur
endem
level
prior
vaccin
introduct
rather
develop
individualbas
prevaccin
screen
program
approach
present
challeng
due
crossreact
dengu
seroassay
talk
conclud
discuss
dengu
vaccin
develop
includ
chimer
vaccin
takeda
butantan
clinic
phase
iii
trial
underway
scott
weaver
univers
texa
medic
branch
galveston
tx
usa
present
updat
epidemiolog
mosquito
vector
transmiss
chikungunya
chikv
zika
zikv
virus
origin
african
enzoot
cycl
recent
spread
asia
follow
america
human
popul
abund
urban
aed
aegypti
mosquito
facilit
major
epidem
nearli
pandem
spread
infect
travel
although
epidem
chikungunya
zika
peak
mani
region
outbreak
continu
especi
southern
cone
south
america
virus
region
africa
asia
europ
chikv
chikv
strain
indian
ocean
lineag
adapt
seri
mutat
envelop
glycoprotein
gene
also
transmit
effici
invas
mosquito
albopictu
fortun
epistat
interact
chikv
strain
circul
america
prevent
adapt
like
chikv
zikv
spread
asia
south
pacif
appear
relat
adapt
evolut
effici
transmiss
aegypti
result
least
part
sever
revers
deleteri
founder
effect
associ
introduct
mani
decad
ago
asia
africa
limit
chikv
adapt
evolut
trace
founder
effect
presum
occur
individu
infect
travel
introduc
virus
accompani
sever
viral
popul
bottleneck
stochast
founder
effect
make
challeng
predict
futur
outbreak
final
hypothes
role
immun
enhanc
result
prior
dengu
viru
infect
sever
congenit
outcom
zikv
infect
discount
sever
epidemiolog
studi
indic
crossprotect
two
flavivirus
aaron
mween
univers
zambia
lusaka
zambia
close
session
present
surveil
viral
zoonos
africa
talk
address
recent
exampl
emerg
highli
danger
viru
unexpect
habitat
present
specif
exampl
emerg
event
high
health
socioeconom
impact
pose
seriou
biosafeti
biosecur
challeng
surveil
bat
major
effort
seropreval
detect
ebola
marburg
virus
recent
major
find
includ
discoveri
highli
pathogen
old
world
arenaviru
lujo
viru
follow
air
transport
fatal
ill
patient
zambia
south
africa
despit
associ
arenavirus
rodent
reservoir
lujo
viru
yet
identifi
anoth
find
base
phylogenet
appar
spread
zair
ebolaviru
associ
sever
widespread
outbreak
ebola
viru
diseas
west
africa
aaron
describ
effort
strengthen
research
zambia
cooper
grant
japanes
research
institut
includ
hokkaido
univers
univers
zambia
financ
world
bank
establish
africa
center
excel
infecti
diseas
human
anim
aceidha
achiev
region
goal
understand
natur
histori
infecti
diseas
promot
train
opportun
young
investig
rang
diagnost
research
technolog
describ
detect
bat
virus
includ
filovirusspecif
igg
elisa
rapid
test
later
flow
assay
fielddeploy
isol
minilab
ongo
investig
avian
influenza
within
wild
bird
reservoir
arenavirus
rodent
also
present
includ
detect
novel
nonpathogen
arenaviru
among
mastomi
natalensi
temporarili
name
luna
lusakanamwala
stephan
becker
marburg
germani
start
session
overview
marburg
viru
marv
ebola
viru
ebov
note
first
document
outbreak
filoviru
diseas
took
place
marburg
germani
amongst
lab
worker
contact
tissu
import
monkey
uganda
first
outbreak
case
includ
secondari
case
case
fatal
rate
cfr
subsequ
filoviru
outbreak
africa
typic
higher
cfr
like
due
unavail
advanc
support
measur
except
case
tai
forest
viru
infect
chimpanze
one
human
case
ivori
coast
known
outbreak
marv
ebov
infect
next
four
decad
confin
central
africa
massiv
west
african
ebola
viru
epidem
show
ebola
outbreak
difficult
contain
sever
consequ
health
infrastructur
whole
countri
signific
impact
economi
outbreak
final
stop
educ
behavior
chang
emphas
commun
engag
key
contain
outbreak
also
wakeup
call
driven
develop
ebola
viru
antivir
vaccin
revers
attitud
necessari
role
research
outbreak
frontrunn
vaccin
recombin
vesicular
stomat
viru
express
surfac
glycoprotein
ebola
viru
subtyp
zair
protect
macaqu
lethal
challeng
importantli
treatment
one
hour
infect
protect
half
anim
suggest
potenti
util
postexposur
therapi
ring
vaccin
becker
discuss
ongo
write
ebola
outbreak
north
kivu
ituri
provinc
democrat
republ
congo
area
current
outbreak
dens
popul
border
uganda
rwanda
south
sudan
despit
intens
threat
secur
humanitarian
crisi
involv
million
intern
displac
peopl
nearli
peopl
alreadi
vaccin
remark
random
control
clinic
trial
three
differ
monoclon
antibodi
treatment
antivir
drug
undertaken
throughout
talk
stephan
highlight
need
improv
prepared
known
well
unknown
emerg
virus
import
goal
gvn
noel
tordo
antivir
strategi
unit
lnstitut
pasteur
pari
franc
began
talk
describ
renov
equip
train
institut
pasteur
de
guine
conakri
guinea
facil
open
june
includ
research
unit
laboratori
work
hemorrhag
fever
virus
rabi
arbovirus
rift
valley
fever
crimean
congo
hemorrhag
fever
yfv
zikv
agent
site
good
model
initi
envis
gvn
tordo
provid
inform
overview
molecular
function
divers
hantavirus
note
envelop
strand
triseg
rna
virus
circul
persist
asymptomat
small
mammal
rodent
insectivor
shrew
mole
bat
hantavirus
distribut
worldwid
may
transmit
human
aerosol
contamin
rodent
excreta
korean
war
unit
nation
soldier
becam
ill
korean
hemorrhag
fever
cfr
notabl
hantavirus
affect
human
includ
hantaan
seoul
puumala
sin
nombr
virus
noel
made
convinc
case
hantavirus
excel
model
evalu
virushost
coevolut
also
present
genet
data
suggest
possibl
insect
origin
basi
differ
diseas
outcom
hantavirus
human
rodent
pathogen
versu
toler
focu
investig
result
also
reveal
increas
neutrophil
upon
puumala
viru
infect
result
delay
apoptosi
nonpathogen
hantavirus
exhibit
effect
observ
support
role
neutrophil
develop
human
nephropathi
induc
puumala
viru
infect
grow
concern
regard
zoonot
risk
human
hantavirus
kept
mind
unexplain
human
epidem
erica
ollmann
saphir
scripp
research
la
jolla
california
usa
present
updat
antibodi
therapeut
ebov
lassa
viru
lasv
ask
best
therapeut
antibodi
virus
make
good
find
also
point
key
need
understand
lead
protect
protect
antibodi
protect
result
either
mechan
neutral
less
well
understood
fc
effector
function
combin
anoth
need
therapeut
antibodi
broadli
reactiv
diverg
filovirus
arenavirus
erica
lead
global
effort
viral
immunotherapeut
consortium
vic
previous
compet
group
vic
chang
normal
paradigm
discoveri
immunotherapeut
antibodi
typic
involv
funnel
favorit
antibodi
singl
group
mice
guinea
pig
nonhuman
primat
tradit
approach
favor
select
neutral
antibodi
vic
compris
laboratori
contin
conduct
comprehens
multidisciplinari
studi
monoclon
antibodi
filovirus
use
glycoprotein
structur
interpret
antibodi
respons
answer
whether
develop
neutral
nonneutr
antibodi
eitheror
may
optim
strategi
combin
neutral
antibodi
mediat
certain
fc
effector
function
erica
group
also
recent
solv
sever
structur
broadli
activ
antifiloviru
antibodi
find
recogn
continuum
epitop
extend
band
across
central
portion
glycoprotein
lmmunogen
design
highlight
key
featur
may
yield
broadli
activ
immun
respons
contrast
filovirus
antibodi
neutral
lasv
predomin
belong
singl
competit
group
recogn
quaternari
epitop
bridg
multipl
subunit
monom
togeth
group
solv
array
structur
understand
featur
princip
neutral
site
led
greatest
activ
ration
structureguid
substitut
increas
potenc
breadth
neutral
includ
major
lineag
lasv
similar
approach
appli
pathogen
develop
broadli
reactiv
antibodi
postexposur
therapi
vaccin
broad
protect
final
talk
session
robert
garri
tulan
univers
new
orlean
louisiana
usa
provid
updat
lassa
fever
first
describ
follow
death
two
missionari
nurs
hospit
outbreak
northeastern
nigeria
subsequ
studi
demonstr
human
acquir
lasv
primarili
via
exposur
viruscontain
urin
fece
main
reservoir
mastomi
natalensi
natal
mastomi
multimamm
mous
humantohuman
transmiss
occur
less
frequent
find
confirm
genet
analysi
lasv
year
surg
case
nigeria
potenti
geograph
expans
mastomi
natalensi
rodent
reservoir
frequent
import
lasv
north
america
europ
emerg
novel
lasv
strain
dens
popul
west
africa
driven
new
initi
develop
countermeasur
lasv
new
initi
includ
develop
lassa
vaccin
cepi
featur
earlier
talk
viral
hemorrhag
fever
consortium
establish
uniqu
clinic
basic
research
program
west
africa
lasv
hyperendem
team
initi
focus
improv
diagnost
assay
base
recombin
lasv
protein
greatli
expand
abil
perform
lasv
serolog
surveil
vhfc
also
deriv
larg
set
human
monoclon
antibodi
lasv
protein
combin
human
monoclon
antibodi
lasv
glycoprotein
abl
cure
macaqu
challeng
virus
two
divers
lineag
lasv
even
treatment
delay
week
cross
et
al
prepar
despit
advanc
fundament
gap
knowledg
immunolog
pathogenesi
ecolog
lassa
fever
persist
hamper
effort
quantifi
risk
design
effect
control
program
peter
openshaw
imperi
colleg
london
uk
report
impact
pathogenesi
respiratori
virus
human
first
document
acut
lung
infect
caus
major
global
burden
diseas
compar
differ
pathogenesi
intervent
strategi
two
major
human
respiratori
pathogen
influenza
viru
rsv
gave
overview
differ
mechan
rsv
interfer
host
immun
system
highlight
global
burden
rsv
children
year
age
age
categori
elderli
address
current
statu
rsv
diseas
prevent
monoclon
antibodi
advent
firstgener
vaccin
hurdl
still
taken
introduct
compar
forc
respiratori
volum
fev
individu
copd
persist
intermitt
rsv
infect
without
rsv
infect
differ
observ
respect
group
clearli
show
rsv
infect
major
impact
fev
therefor
sever
copd
exacerb
subsequ
show
import
balanc
immun
respons
rsv
clinic
studi
children
bronchiol
without
rsv
infect
viral
load
immun
mediat
gene
express
level
measur
mucos
sampl
compar
mild
moder
sever
infect
final
present
network
scientist
work
experiment
infect
human
volunt
sever
pathogen
includ
rsv
influenza
viru
elabor
potenti
approach
ab
osterhau
tihoriz
hannov
germani
gave
overview
dozen
human
anim
virus
group
discov
rotterdam
hannov
past
decad
larg
benefit
advent
new
molecular
technolog
human
virus
includ
influenza
virus
human
metapneumoviru
well
sarsmersand
human
coronavirus
addit
address
lesson
recent
rinderpest
erad
eventu
erad
measl
present
recent
document
explan
group
measl
induc
immun
suppress
caus
elimin
memori
b
cell
measl
viru
infect
explain
identif
character
sar
coronaviru
caus
sar
fulfil
koch
postul
use
monkey
model
contribut
control
sar
shortli
emerg
ten
year
discoveri
sar
group
discov
mer
coronaviru
caus
agent
mer
identif
dromedari
camel
sourc
infect
identif
receptor
success
test
candid
mer
vaccin
speci
highlight
import
one
health
approach
combat
human
infect
sourc
final
summar
work
anim
influenza
virus
sourc
zoonot
influenza
infect
epidem
eventu
pandem
import
develop
prepared
plan
futur
influenza
pandem
highlight
michel
crank
vaccin
research
center
niaid
usa
gave
updat
result
phase
clinic
trial
stabil
rsv
prefus
f
glycoprotein
vaccin
show
rsv
f
glycoprotein
structur
larg
determin
immunogen
give
overview
current
knowledg
f
glycoprotein
rsv
biolog
present
develop
stabil
pref
rsv
vaccin
antigen
interim
result
clinic
trial
vaccin
candid
healthi
adult
first
highlight
problem
firsv
vaccineenhanc
diseas
year
occur
well
mechan
antibodi
mediat
enhanc
could
elicit
advers
event
rsv
vaccin
monoclon
antibodi
develop
snapshot
present
show
mani
product
current
pipelin
address
structur
prefus
f
glycoprotein
import
conform
depend
natur
neutralizationsensit
epitop
develop
rsv
vaccin
shown
elicit
potent
neutral
activ
rsva
rsvb
shown
pref
specif
antibodi
bind
apex
site
pref
site
final
ongo
work
b
cell
respons
well
clinic
outcom
vaccin
studi
address
adolfo
garcia
sastr
icahn
school
medicin
mount
sinai
new
york
usa
gave
histor
overview
evolut
spread
influenza
virus
zoonot
event
human
case
pandem
epidem
result
anim
human
influenza
viru
infect
highlight
need
univers
influenza
vaccin
provid
broader
protect
made
prepar
pandem
might
also
serv
better
control
epidem
influenza
introduc
concept
hastembas
univers
flu
vaccin
induct
protect
level
stalkreact
antibodi
chimer
ha
stalk
construct
follow
subsequ
immun
chimer
ha
stalk
construct
differ
influenza
subtyp
protect
upon
challeng
yet
anoth
ha
subtyp
viru
provid
prove
concept
approach
mice
protect
prove
antibodymedi
transferchalleng
experi
subsequ
experi
ferret
show
live
attenu
vaccin
follow
inactiv
chimer
ha
vaccin
induc
ha
stem
na
antibodi
high
level
protect
toward
challeng
heterotyp
influenza
virus
given
promis
result
obtain
combin
differ
innov
approach
next
step
prove
valid
develop
concept
human
trial
meagan
deme
institut
human
virolog
baltimor
md
usa
address
major
problem
respiratori
viral
infect
immunocompromis
solid
organ
haematopoiet
stemcel
transplant
hsct
recipi
cumul
incid
latter
group
eventu
prove
approach
although
sever
virus
prove
involv
coronaand
rhinovirus
appear
common
pathogen
studi
also
case
lung
transplant
recipi
virus
two
group
tend
persist
prolong
period
time
patient
haematolog
malign
hsct
recipi
lower
respiratori
tract
infect
seen
studi
period
associ
mortal
rate
even
depend
viru
involv
effect
success
rate
limit
sever
antivir
biolog
respons
modifi
strategi
differ
therapeut
target
depend
respect
virus
discuss
conclud
challeng
face
respiratori
viru
infect
immunocompromis
solid
organ
hsct
recipi
may
requir
uniqu
multiprong
strategi
potent
antivir
biolog
respons
modifi
target
conserv
mediat
pathogenesi
harri
r
dalton
truro
unit
kingdom
describ
hepat
e
viru
hev
caus
neurolog
diseas
hev
infect
mainli
genotyp
major
health
problem
develop
countri
asia
africa
consid
littl
relev
develop
countri
purcel
emerson
recent
data
present
refut
latter
assumpt
show
hev
infect
also
endem
europ
dalton
et
al
hev
infect
europ
mainli
acquir
via
pig
wild
boar
porcin
zoonosi
commonli
asymptomat
chronic
hev
infect
subsequ
cirrhosi
may
develop
immunosuppress
individu
includ
transplant
patient
kamar
et
al
variou
neurolog
diseas
particularli
guillainbarr
syndrom
gb
neuralg
amyotrophi
na
discuss
debilit
extrahepat
manifest
hev
infect
commonli
individu
without
overt
sign
liver
diseas
zheng
et
al
scanvion
et
al
evid
recent
hev
infect
identifi
gb
patient
hevassoci
na
uniqu
clinic
present
mclean
et
al
causal
relationship
hev
neurolog
syndrom
indic
hev
neurotrop
viru
warrant
futur
studi
identifi
key
viru
host
factor
develop
novel
intervent
strategi
final
hypothesi
hev
caus
miscarriag
human
discuss
thoma
institut
molecular
virolog
cell
biolog
friedrichloefflerinstitut
greifswald
insel
riem
germani
describ
past
achiev
current
challeng
control
rabi
viru
rabv
infect
wildlif
reservoir
despit
larg
varieti
rabv
reservoir
speci
worldwid
major
human
rabi
case
due
dog
bite
prevent
vaccin
dog
high
risk
area
present
data
support
concept
immun
wildlif
oral
rabi
vaccin
orv
consist
liveattenu
recombin
livevector
rabv
vaccin
speci
target
bait
import
compon
holist
rabi
manag
program
elimin
rabv
wildlif
reservoir
longterm
largescal
orv
program
fox
led
almost
complet
elimin
fox
rabi
western
europ
north
america
et
al
maki
et
al
howev
rabv
continu
adapt
perpetu
within
wildlif
speci
pose
seriou
health
risk
domest
anim
human
freir
de
carvalho
et
al
discuss
challeng
ahead
rabi
elimin
program
feasibl
certain
wild
reservoir
speci
warrant
sustain
polit
financi
support
upcom
decad
fook
et
al
challeng
discuss
includ
issu
better
insight
need
target
speci
eg
multispeci
reservoir
speci
host
speci
shift
event
wallac
et
al
optim
vaccin
bait
ie
bait
fit
speci
johnson
et
al
optim
deliveri
distribut
system
eg
airplan
specif
site
sterner
et
al
optim
vaccin
strategi
eg
vaccin
interv
bait
densiti
sterner
et
al
vaccin
strain
eg
minim
effect
orv
dose
uptak
differ
per
speci
zhugunissov
et
al
justin
jh
chu
depart
microbiolog
immunolog
school
medicin
nation
univers
singapor
describ
clinic
manifest
virushost
interact
hand
foot
mouth
diseas
hfmd
incid
human
neurotrop
enterovirus
caus
hfmd
patient
admit
hospit
includ
human
enteroviru
infect
associ
sever
even
fatal
neurolog
complic
young
children
steadili
increas
singapor
past
decad
caus
signific
healthcar
econom
burden
teo
chu
use
genomewid
sirna
mirna
screen
coupl
proteom
profil
lab
identifi
numer
host
suscept
resist
factor
affect
infect
leong
et
al
wu
et
al
host
factor
pathway
identifi
subject
downstream
studi
chu
lab
identifi
role
differenti
diseas
outcom
develop
novel
intervent
strategi
next
report
studi
address
unmet
need
effect
safe
antivir
chu
lab
develop
highthroughput
screen
platform
lead
identif
highli
potent
noncytotox
antivir
flavonoid
marvasflavon
natur
compound
extract
citru
fruit
peel
specif
target
intern
ribosom
entri
site
iri
min
et
al
besid
inhibit
replic
enterovirus
vitro
marvasflavon
appear
highli
effect
mous
model
promis
candid
develop
georg
mgm
verjan
depart
virosci
erasmu
mc
rotterdam
netherland
describ
virushost
interact
herpesviru
infect
human
nervou
tissu
rodent
model
central
studi
pathogenesi
neurodegen
diseas
model
fulli
recapitul
human
diseas
investig
ransohoff
studi
virushost
interact
differ
human
herpesvirus
human
brain
tissu
epsteinbarr
viru
ebv
sensori
ganglia
herp
simplex
viru
hsv
varicellazost
viru
vzv
present
first
associ
ebv
multipl
sclerosi
ms
geginat
et
al
address
demonstr
despit
absenc
ebv
protein
nucleic
acid
cerebrospin
fluid
csf
brain
tissu
ebv
reactiv
tcell
select
accumul
csf
diseas
brain
tissu
ms
patient
suggest
local
ebvspecif
tcell
immun
contribut
ms
patholog
van
nierop
et
al
second
identif
character
novel
splice
protein
code
vzv
transcript
vzv
latenc
transcript
vl
present
vlt
select
express
latent
vzvinfect
neuron
human
trigemin
ganglia
tg
appear
block
lytic
vzv
infect
depledg
et
al
third
role
tcell
control
latent
human
tg
describ
contrast
vzv
cell
select
retain
dual
latent
infect
human
tg
kinchington
et
al
limit
number
protein
recogn
particularli
target
cell
multipl
tg
donor
propos
potenti
vaccin
candid
van
velzen
et
al
studi
present
highlight
import
studi
virushost
interact
human
neurotrop
virus
diseaserelev
tissu
speci
human
nervou
tissu
ludlow
et
al
jame
j
sejvar
nation
center
emerg
zoonot
diseas
center
diseas
control
prevent
atlanta
georgia
usa
present
updat
epidemiolog
clinic
manifest
flavivirusinduc
neurolog
diseas
japanes
enceph
viru
jev
remain
common
caus
epidem
enceph
asia
primarili
affect
children
case
fatal
rate
third
surviv
children
signific
neurolog
sequela
west
nile
viru
wnv
emerg
signific
caus
enceph
us
start
outbreak
new
york
subsequ
spread
throughout
us
southern
canada
current
common
caus
enceph
north
america
yeung
et
al
past
decad
wnv
activ
increas
central
southern
europ
barzon
jev
wnv
infect
mostli
asymptomat
caus
mild
diseas
includ
fever
headach
infect
individu
neuroinvas
diseas
present
enceph
associ
movement
disord
yeung
et
al
anterior
myeliti
appear
common
wnv
infect
seizur
jev
infect
also
poorer
prognosi
compar
patient
wnvassoci
neurolog
diseas
compar
jev
wnv
causal
virusinduc
neurolog
sign
denvinfect
individu
remain
unclear
warrant
advanc
neurodiagnost
often
unavail
dengueendem
area
li
et
al
wherea
associ
denv
gb
formal
establish
extrem
unusu
high
incid
gb
area
zikv
outbreak
south
pacif
south
central
america
support
strong
evid
implic
zikv
infect
associ
gb
sejvar
furthermor
zikv
present
import
caus
congenit
abnorm
eg
microcephali
wide
spectrum
neurolog
diseas
includ
meningoenceph
enceph
indic
zikv
neurotrop
viru
mieryteranromero
et
al
hubert
endtz
foundat
lyon
franc
gave
talk
respiratori
infect
among
refuge
unit
nation
high
commission
refuge
unhcr
report
total
number
million
forcibl
displac
person
worldwid
syrian
refuge
crisi
largest
approxim
million
displac
person
five
million
civilian
cross
border
million
took
refug
lebanon
rohingya
forc
myanmar
bangladesh
fastest
grow
crisi
surviv
small
restrict
piec
land
near
cox
bazar
chittagong
district
south
bangladesh
morbid
associ
acut
respiratori
infect
acut
lower
respiratori
infect
among
lead
caus
mortal
among
refuge
popul
displac
popul
includ
refuge
risk
neg
outcom
secondari
alri
malnutrit
poor
live
condit
low
vaccin
statu
rough
climat
condit
overcrowd
understand
epidemiolog
etiolog
alri
africa
import
relat
vaccin
develop
implement
two
casecontrol
studi
coordin
fondat
local
partner
institut
investig
alri
etiolog
studi
involv
patient
control
per
countri
princip
object
studi
estim
proport
distribut
communityacquir
pneumonia
attribut
specif
viral
bacteri
pathogen
popul
attribut
fraction
paf
patient
children
major
ari
death
sever
ill
episod
due
alri
filmarray
techniqu
specif
pcr
diagnost
use
identifi
variou
microorgan
involv
alri
studi
among
rohingya
still
ongo
preliminari
result
studi
among
syrian
refuge
report
meet
overal
influenza
rsv
rhinoviru
commonli
isol
microorgan
streptococcu
pneumonia
rank
place
influenza
viru
commonli
isol
microorgan
children
year
age
paf
adult
paf
rsv
came
first
among
children
paf
studi
help
us
better
understand
etiolog
alri
optim
treatment
algorithm
ration
use
new
vaccin
among
displac
person
gvn
network
expand
incorpor
follow
center
univers
nebraska
medic
center
unmc
west
african
center
cell
biolog
infecti
pathogen
waccbip
univers
ghana
colombiawisconsin
onehealth
consortium
cwohc
gvnsingapor
center
excel
uganda
viru
research
institut
uvri
gvn
also
incorpor
one
affili
institut
africa
center
excel
infecti
diseas
human
anim
aceidha
univers
zambia
lusaka
affili
via
two
gvn
center
excel
hokkaido
univers
hu
sapporo
japan
univers
colleg
dublin
dublin
ucd
ireland
past
year
gvn
continu
hepat
c
train
hepat
b
databas
develop
program
india
gvn
zika
serum
bank
regard
train
gvn
host
gvn
cours
emerg
leader
medic
virolog
expand
commun
scholar
scientist
countri
past
year
gvn
activ
public
inform
advocaci
particularli
commun
public
effort
gvn
center
carri
ebola
nipah
outbreak
gvn
strong
advocaci
role
issu
open
letter
request
organ
support
promot
gvn
prevent
strategi
year
gvn
anticip
prepared
task
forc
creat
goal
task
forc
provid
novel
approach
delin
futur
next
epidem
merg
mathemat
model
epidemiolog
genom
medicin
public
health
train
educ
workshop
africa
new
gener
scientist
medic
doctor
contribut
fight
bioterror
provid
expert
advic
global
public
health
strategi
cochair
task
forc
elodi
ghedin
phd
director
center
genom
system
biolog
new
york
univers
unit
state
giusepp
ippolito
md
scientif
director
nation
institut
infecti
diseas
lazzaro
spallanzani
itali
first
step
order
develop
meaning
long
term
strategi
creat
questionnair
help
delin
prioriti
research
prepared
respons
event
caus
viral
pathogen
meanwhil
readili
engag
small
scale
action
concret
engag
gvn
prepar
futur
action
plan
aim
questionnair
help
develop
common
understand
among
gvn
center
excel
prioriti
appropri
make
practic
recommend
chang
identifi
capac
avail
network
result
analyz
publish
posit
paper
gvn
plan
address
local
need
train
educ
develop
region
gvn
unit
team
expert
virologist
group
geograph
region
current
take
first
step
toward
establish
follow
region
africa
south
east
asia
south
america
europ
plan
region
unit
world
gvn
also
plan
host
gvn
cours
baltimor
week
juli
th
august
much
focu
gvn
implement
gvn
anticip
prepared
task
forc
partnership
global
public
health
institut
goarn
network
gvn
intern
meet
take
place
barcelona
